Monexe (Valsartan, Hydrochlorothiazide)

Valsartan/Hydrochlorothiazide, the active ingredients in Monexe, are an Angiotensin II receptor blocker and a thiazide diuretic presented as a tablet for oral use. They treat hypertension in adults by lowering blood pressure and reducing fluid overload. GNH USA supplies Monexe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monexe, a combination of valsartan and hydrochlorothiazide, is used in the management of hypertension, a condition characterized by elevated arterial pressure.

Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk. Essential hypertension: provides effective control when monotherapy is insufficient. Hypertension with fluid retention: adds diuretic effect to improve volume management.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia (high potassium levels) - Angioedema or severe allergic reaction - Significant drop in blood pressure (hypotension) - Blood count abnormalities (e.g., leukopenia)

Before initiating therapy, clinicians should assess renal function, electrolyte status, and blood pressure stability.

Renal function: monitor serum creatinine and eGFR regularly. Electrolytes: check potassium and sodium levels, especially when combined with other diuretics. Pregnancy: avoid use; teratogenic risk is unknown. Concurrent NSAIDs: increased risk of renal impairment; monitor kidney function. Hypotension: caution in volume‑depleted patients to prevent symptomatic low blood pressure. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Monexe may interact with several medicines that affect blood pressure, electrolytes, or renal function.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment - Potassium‑sparing diuretics or potassium supplements (risk of hyperkalemia) - Concurrent use of ACE inhibitors or other ARBs (excessive renin‑angiotensin blockade)

Moderate Interactions (Monitor Closely): - NSAIDs (may reduce antihypertensive effect and impair renal function) - Lithium (increased lithium levels, risk of toxicity)